(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN), Plus ...

In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

Today, the trees remain a symbol of goodwill between Japan and the U.S. AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer Over the weekend ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

at 02:35 ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients ...

At close: 5:29:49 PM GMT+2 ...

Recklessness and greed, when combined with a total lack of empathy, are a dangerous mix in the top tiers of finance.